Ref ID: 18714
Author:
T. Lecompte, MD – Research Assistant 1, C. Garzoni, MD – Attending Physician 2, N. Mueller, MD – Attending Physician 3, G. Kralidis, MD – Research Assistant 4, O. Manuel, MD – Attending Physician 5, M. Weiser, MD – Attending Physician 4, C. Berger, M
Author address:
1Univ. Hosp., Geneva, Switzerland, 2Clinica Luganese, Lugano, Switzerland, 3Univ. Hosp., Zurich, Switzerland, 4Univ. Hosp., Basel, Switzerland, 5Univ. Hosp., Lausanne, Switzerland, 6Cantonal Hosp., St.Gallen, Switzerland.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: To describe the epidemiologic characteristics of fungal infections (FI) in solid organ transplant (SOT) recipients in the area of modern immunosuppression and prophylactic strategies. Methods: Prospective observational study involving all patients included in the Swiss Transplant Cohort Study (STCS) between May 2008 and November 2011 with at least 6 months of follow-up. FI was defined according to EORTC definitions. Results: Among 1053 patients analyzed, 96 patients had 125 FI. The numbers of FI per transplant were: kidney; 68, liver; 25, heart; 17, lung; 13, kidney-pancreas; 2.The most frequent sites of FI were mucocutaneous (43) and respiratory tract (35). Median times until FI after transplantation were 3.4, 1.6, 1, and 1.9 months respectively for kidney, heart, liver and lung transplants. Ninety three percent (117/125) of FI were treated, with a single antifungal in 105 cases. Death occurred in 26/96(27%) patients with FI, as compared to 65/820 (8%) infected patients without FI. Conclusions: in the STCS FI occurred in 9% of transplant recipients, mostly before 6 months post-transplantation. Candida and Aspergillus were the most common isolated fungi. Despite the treatment of nearly all FI the overall mortality in these patients was high. Further analyses are ongoing to assess risk factors for FI and the influence of prophylaxis on incidence of both colonization and infection in SOT recipients, given the local fungal resistance patterns.
Abstract Number: T-343
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a